ATRS Antares Pharma Inc

Price (delayed)

$4.13

Market cap

$697.14M

P/E Ratio

11.16

Dividend/share

N/A

EPS

$0.37

Enterprise value

$688.28M

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has ...

Highlights
Antares Pharma's equity has surged by 135% YoY and by 6% QoQ
ATRS's P/E is 67% below its last 4 quarters average of 34.2
ATRS's quick ratio is down by 37% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of ATRS
Market
Shares outstanding
168.8M
Market cap
$697.14M
Enterprise value
$688.28M
Valuations
Price to earnings (P/E)
11.16
Price to book (P/B)
5.5
Price to sales (P/S)
4.37
EV/EBIT
33.83
EV/EBITDA
29.54
EV/Sales
4.34
Earnings
Revenue
$158.6M
EBIT
$20.35M
EBITDA
$23.3M
Free cash flow
$7.84M
Per share
EPS
$0.37
Free cash flow per share
$0.05
Book value per share
$0.75
Revenue per share
$0.95
TBVPS
$1.26
Balance sheet
Total assets
$218.46M
Total liabilities
$92.23M
Debt
$46.8M
Equity
$126.23M
Working capital
$61.37M
Liquidity
Debt to equity
0.37
Current ratio
1.85
Quick ratio
1.37
Net debt/EBITDA
-0.38
Margins
EBITDA margin
14.7%
Gross margin
67.6%
Net margin
39.3%
Operating margin
21.1%
Efficiency
Return on assets
34.2%
Return on equity
67.8%
Return on invested capital
17.2%
Return on capital employed
13.9%
Return on sales
12.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATRS stock price

How has the Antares Pharma stock price performed over time
Intraday
-1.43%
1 week
-7.19%
1 month
1.23%
1 year
43.4%
YTD
3.51%
QTD
0.49%

Financial performance

How have Antares Pharma's revenue and profit performed over time
Revenue
$158.6M
Gross profit
$107.19M
Operating income
$33.47M
Net income
$62.35M
Gross margin
67.6%
Net margin
39.3%
The company's operating margin has surged by 185% YoY and by 39% QoQ
The operating income has grown by 47% from the previous quarter
ATRS's gross profit is up by 27% year-on-year and by 12% since the previous quarter
ATRS's revenue is up by 19% YoY and by 6% QoQ

Growth

What is Antares Pharma's growth rate over time

Valuation

What is Antares Pharma stock price valuation
P/E
11.16
P/B
5.5
P/S
4.37
EV/EBIT
33.83
EV/EBITDA
29.54
EV/Sales
4.34
ATRS's P/E is 67% below its last 4 quarters average of 34.2
Antares Pharma's EPS has increased by 9% QoQ
Antares Pharma's equity has surged by 135% YoY and by 6% QoQ
The price to book (P/B) is 47% lower than the 5-year quarterly average of 10.4 and 15% lower than the last 4 quarters average of 6.5
The P/S is 27% below the 5-year quarterly average of 6.0 but 15% above the last 4 quarters average of 3.8
ATRS's revenue is up by 19% YoY and by 6% QoQ

Efficiency

How efficient is Antares Pharma business performance
The ROIC has increased by 42% from the previous quarter
Antares Pharma's return on sales has increased by 39% QoQ
Antares Pharma's return on equity has decreased by 11% QoQ

Dividends

What is ATRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRS.

Financial health

How did Antares Pharma financials performed over time
The total assets is 137% greater than the total liabilities
The total assets has surged by 60% year-on-year and by 2.8% since the previous quarter
The current ratio has contracted by 39% YoY and by 8% from the previous quarter
Antares Pharma's debt is 63% less than its equity
Antares Pharma's equity has surged by 135% YoY and by 6% QoQ
The debt to equity has dropped by 57% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.